Simi Valley, California 93063

  • Renal Disease


The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.


Inclusion Criteria: - End stage renal disease patients on dialysis for at least 90 days deemed to be at low risk by the investigator for being hospitalized or have concurrent infections - Serum phosphorous level > 5 mg/dl - Stable phosphate binder regimen for 2 week prior to enrollment - Stable dose of Vitamin D for 4 weeks prior to enrollment - Stable calcimimetic dose for 4 week prior to enrollment Exclusion Criteria: - patients who are pregnant - patients who have pre existing thrombocytopenia defined as a platelet count of <100 x 109/L - abnormal LFTs - baseline CRP > 15 g/dl - known sensitivity to any of the active ingredients - patients who are currently enrolled in a clinical trial, or who have been in a clinical trial in the last six months - are currently taking any immunosuppressive medications



Primary Contact:

Study Director
Ray Chow, PhD

Backup Contact:


Location Contact:

Simi Valley, California 93063
United States

Kant Tucker, MD
Phone: 805-433-7500

Site Status: Recruiting

Data Source:

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.